Logo

Biocon and Mylan Launch Semglee (biosimilar- Insulin Glargine) in Australia

Share this

Biocon and Mylan Launch Semglee (biosimilar- Insulin Glargine) in Australia

Shots:

  • Biocon & Mylan launch the Semglee (insulin glargine solution for injection 100 IU/mL in a 3mL pre-filled pen) as the first Insulin Glargine biosimilar in Australia available on the PBS
  • The TGA approval is based on the data demonstrated high bio-similarity of Semglee with the reference- Insulin Glargine. The launch of Semglee will increase patients access to the therapy and reduces the cost burden for PBS
  • Insulin glargine (qd) is a long-acting basal insulin analog- helps to control the blood sugar levels in diabetes and is one of the three insulin analogs being co-developed by Mylan and Biocon. Mylan holds exclusive commercialization rights of Semglee in the US- Canada- Australia- New Zealand & EU while Biocon grasps exclusive commercialization rights in Japan & few emerging markets with co-exclusive commercialization rights with Mylan in ROW

Click here to­ read full press release/ article | Ref: Biocon | Image: Pinterest


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions